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Cyrene	as	a	Bio-based	Solvent	for	HATU	Mediated	Amide	Coupling	
Kirsty	L.	Wilson,a	Jane	Murray,b	Craig	Jamiesona	and	Allan	J.	B.	Watsonc*	
Amide	bonds	are	one	of	the	underpinning	linkages	in	all	living	systems	and	are	fundamental	within	drug	discovery.	Current	
methods	 towards	 their	 synthesis	 frequently	 rely	 on	 the	 use	 of	 dipolar	 aprotic	 solvents;	 however,	 due	 to	 increasingly	
stringent	 regulations	 and	 growing	 societal	 pressures,	 safe	 and	 more	 sustainable	 alternatives	 are	 highly	 sought	 after.	
Herein,	 we	 evaluate	 the	 application	 of	 the	 bio-based	 solvent	 Cyrene™	 in	 the	 HATU	mediated	 synthesis	 of	 amides	 and	
peptides.	We	found	that	Cyrene	functioned	as	a	competent	replacement	for	DMF	in	the	synthesis	of	a	series	of	lead-like	
compounds	and	dipeptides	(25	examples,	63-100%).	
	
Introduction	
The	 amide	 functionality	 is	 ubiquitous	 throughout	 the	
natural	world,	forming	the	backbone	of	essential	biomolecules	
(e.g.	 proteins)	 as	 well	 as	 many	 widely	 used	 materials	 (e.g.	
polyamides).1,2	 Additionally,	 the	 amide	 moiety	 has	 profound	
importance	 to	 modern	 pharmaceutical	 development.	 This	 is	
clearly	 demonstrated	 throughout	 the	 chemical	 literature,	
where	amide	bond	formation	is	consistently	highlighted	as	the	
most	 frequently	 performed	 transformation	 in	 medicinal	
chemistry.3-5	 Indeed,	 Brown’s	 recent	 analysis	 of	 past	 and	
present	 synthetic	 methodologies	 within	 medicinal	 chemistry	
revealed	 that	 50%	of	manuscripts	 surveyed	 (a	 representative	
data	 set	 of	 125	 papers	 taken	 from	 J.	 Med.	 Chem.	 in	 2014)	
contained	the	transformation	in	the	context	of	small	molecule	
synthesis.	 The	 authors	 also	 note	 that	 the	 amide	 functionality	
occurs	 in	>50%	of	pharmaceutical	drug	discovery	patents	and	
journals	 (as	 calculated	 by	 the	 IBEX	 database).3	 In	 addition	 to	
these	 significant	 statistics	within	 small	molecule	 drug	 design,	
the	number	of	peptides	being	approved	for	therapeutic	use	is	
growing	 dramatically.	 Analysis	 of	 the	 peptide	 drug	 market	
carried	out	by	Nuss	 revealed	 that,	as	of	2016,	 the	number	of	
peptides	approved	as	drugs	was	56	while	a	 further	178	were	
involved	 in	 clinical	 trials	 (Phase	 I-III).6	 As	 such,	 efficient	
methods	towards	their	formation	are	highly	sought	after.		
Typically,	amides	are	formed	by	the	direct	condensation	of	
carboxylic	acids	and	amines,	usually	using	an	activator	of	some	
kind,	which	is	attractive	due	to	the	high	abundance	of	starting	
materials.	Established	methods	employ	coupling	reagents	such	
as	 HATU7	 and	 COMU,8	 and	 commonly	 rely	 on	 the	 use	 of	
dipolar	aprotic	solvents,	the	continued	use	of	which	is	of	great	
concern	 due	 to	 the	 safety	 issues	 they	 pose.	 Exposure	 to	
solvents	such	as	DMF	and	NMP	is	associated	with	reproductive	
toxicity	 and,	 as	 such,	 have	 been	 placed	 on	 the	 Registration,	
Evaluation,	Authorisation	and	Restriction	of	Chemicals	(REACH)	
list	of	 substances	of	very	high	concern	with	NMP	additionally	
recommended	for	inclusion	on	the	REACH	authorisation	list.9,10		
In	 this	 respect,	 solvent	selection	and	more	specifically	 the	
reduction	in	usage	of	dipolar	aprotic	solvents	such	as	DMF	and	
NMP	 has	 been	 designated	 a	 focal	 area	 by	 leading	
pharmaceutical	 companies	and	academic	groups.11	As	 such,	a	
number	 of	 tools	 and	 guides	 have	 been	 published	 to	 allow	
chemists	to	identify	suitable	alternatives	and	make	changes	to	
their	 reaction	 manifold	 to	 align	 with	 current	 environmental	
advisory	guidelines.12-17	Despite	 these	efforts	and	 increasingly	
stringent	regulations,	the	use	of	dipolar	aprotic	solvents	is	still	
widespread.18	This	is	due	to	the	superior	solubilising	power	of	
DMF	and	NMP,	which	is	why	they	are	commonly	encountered	
in	 amide	 bond	 formation	 and,	 more	 specifically	 in	 the	
synthesis	of	peptides.			
Efforts	have	been	made	towards	highlighting	direct	solvent	
replacement	strategies	within	amide	bond	formation.	We	have	
previously	 evaluated	 the	 use	 of	 selected	 alternative	 solvents	
within	 four	 benchmark	 amide	 bond	 forming	 reactions,	
demonstrating	 that	 CH2Cl2	 and	 DMF	 could	 successfully	 be	
replaced	by	more	benign	solvents.19	More	recently,	a	series	of	
papers	 have	 been	 published	 detailing	 the	 replacement	 of	
dipolar	 aprotic	 solvents	 within	 solid	 phase	 peptide	 synthesis	
(SPPS).20-24	 In	 addition	 to	 these	 important	 contributions,	
emerging	 micellar	 technology	 has	 also	 allowed	 for	 the	
formation	of	amide	bonds	in	aqueous	media.25	
	
Figure	1.	Physical	properties	of	Cyrene	and	DMF	
O
O
O
Cyrene (1)
•  B. Pt.: 203 °C
•  Density: 1.25 g/mL
•  Dipolarity (π*): 0.93
•  B. Pt.: 153 °C
•  Density: 0.94 g/mL
•  Dipolarity (π*): 0.88
DMF
H
O
N
Me
Me
ARTICLE	 Journal	Name	
2 	|	J.	Name.,	2012,	00,	1-3	 This	journal	is	©	The	Royal	Society	of	Chemistry	20xx	
Please	do	not	adjust	margins	
Please	do	not	adjust	margins	
In	 addition	 to	 the	 safety	 aspects	 surrounding	 the	 use	 of	
conventional	 solvents,	 growing	 societal	 and	 political	 pressure	
towards	 the	 greening	 of	 chemical	 industries	 places	 emphasis	
on	 the	 reduction	 of	 petroleum	 based	 chemicals	 in	 favour	 of	
those	 derived	 from	 sustainable	 sources.26	 To	 address	 this	
movement,	many	Green	Chemistry	initiatives	within	academia	
and	 industry	 are	 exploring	 solvents	 which	 can	 be	 obtained	
from	biomass.27-35	 	Dihydrolevoglucosenone	 (CyreneTM,	Figure	
1),	 which	 can	 be	 accessed	 from	 cellulose	 in	 two	 steps,	 has	
been	shown	to	possess	similar	physical	properties	to	DMF	and	
other	 dipolar	 aprotic	 solvents	 and	 is	 not	 currently	 associated	
with	 any	 harmful	 effects.34-40	 Cyrene	 has	 previously	
demonstrated	 successful	 application	 in	 materials	
chemistry,41,42	 in	 addition	 to	 synthetic	 organic	
transformations.43-45	 Based	 on	 our	 interest	 in	 solvent	
replacement	strategies,21,46-49	we	are	pleased	to	report	the	use	
of	Cyrene	as	a	bio-based	solvent	in	amide	bond	formation.	
Results	and	discussion	
To	investigate	the	capacity	of	Cyrene	as	a	solvent	in	amide	bond	
formation	 we	 selected	 N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-
b]pyridin-	 1-ylmethylene]-	 N-methyl-	 methanaminium	
hexafluorophosphate	 N-oxide	 (HATU)	 as	 the	 coupling	 reagent7	 in	
the	benchmark	coupling	of	p-toluic	acid	1a	and	aniline	2a	(Table	1).		
Table	1.	Reaction	Optimisationa	
	
Entry	 Reaction	conditions	
Conversion	
(µ	±	σ	%)b	
1	 DIPEA	(2	equiv.),	24	hc	 87	±	13	
2	 DIPEA	(2	equiv.),	1	hc	 84	±	21	
3	 DIPEA	(2	equiv.),	1	h,	200	rpm	 73	±	3	
4	 DIPEA	(2	equiv.),	1	h,	400	rpm	 71	±	3	
5	 DIPEA	(2	equiv.),	1	h,	800	rpm	 96	±	7	
6	 DIPEA	(3	equiv.),	1	h,	400	rpm	 92	±	2	
7	 DIPEA	(3	equiv.),	1	h,	400	rpmd	 100	±	0	
a	p-Toluic	acid	 (1	equiv.,	0.25	mmol),	aniline	 (1.1	equiv.,	0.275	mmol),	HATU	
(1.2	 equiv.,	 0.3	 mmol).	 b	 %	 conversion	 calculated	 by	 1H	 NMR	 using	 1,4-
dinitrobenzene	 as	 an	 internal	 standard.	 Presented	 as	 an	 average	 with	
standard	deviation	as	a	measure	of	consistency.	n=3.	c	Variable	stirring	rate.	d	
DMF	as	solvent.	
We	found	that	the	initial	reaction	proceeded	smoothly	allowing	
a	reduced	reaction	time	of	1	h	(Entry	2).	However,	whilst	high	yields	
of	 3a	 were	 recorded	 further	 repetitions	 failed	 to	 deliver	
consistency.	We	found	that	this	was	due	to	variable	stirring	rate	and	
as	 such,	 stringent	 control	 of	 this	 factor	 allowed	 us	 to	 establish	
consistency	(Entry	3).	Upon	increasing	the	stirring	rate	higher	yields	
with	 little	 variance	 could	 be	 achieved	 (Entry	 3-5).	 	 Cyrene	 is	 a	
viscous	liquid,	which	we	believe	gives	rise	to	sub-optimal	mixing	at	
slow	 stirring	 rates.	 However,	 by	 increasing	 the	 stoichiometry	 of	
DIPEA	we	observed	a	decreased	dependency	of	yield	on	stirring	rate	
(Entry	6).	Variation	of	coupling	reagent	and	base	failed	to	offer	any	
improvement	on	conversion	(see	ESI).	
We	sought	to	investigate	the	utility	of	the	optimized	conditions	
(Table1,	Entry	6)	 in	the	coupling	of	a	range	of	carboxylic	acids	and	
amines	 (Scheme	 1).	 Variation	 of	 the	 carboxylic	 acid	 and	 amine	
components	 was	 broadly	 successful	 (15	 examples,	 63-100%)	 with	
alkyl	 (e.g.,	3g,	3j)	and	aryl	 (e.g.,	3k,	3m)	moieties	of	both	coupling	
partners	 tolerated.	 In	 addition	 to	 primary	 amines	 we	 found	 that	
both	cyclic	(e.g.,	3c,	3i)	and	acyclic	(e.g.,	3f)	secondary	amines	could	
be	coupled	 in	high	yields.	 In	 the	cases	where	comparatively	 lower	
yields	were	reported,	such	as	3n,	we	found	that	the	remaining	mass	
balance	was	made	up	of	unreacted	activated	ester.	
	
Scheme	 1.	 HATU	 mediated	 amide	 bond	 formation:	 Scope	 of	 the	 transformation.	
Isolated	yields.	Acid	(1	equiv.,	0.25	mmol),	amine	(1.1	equiv.,	0.275	mmol),	HATU	(1.2	
equiv.,	0.3	mmol),	DIPEA	(3	equiv.,	0.75	mmol),	Cyrene	(1.25	mL,	0.2	M),	rt,	1	h.	
We	 next	 applied	 these	 conditions	 in	 the	 synthesis	 of	
peptides	 (Scheme	 2).	 Again,	 high	 yields	 are	 reported	 in	 the	
coupling	 of	 protected	 amino	 acids,	 with	 a	 broad	 scope	 of	
functionality	demonstrated	(9	examples,	63-100%).	In	addition	
to	 amino	 acids	 whose	 side	 chains	 bore	 alkyl	 and	 aryl	
substituents	 (e.g.,	 6a	 and	 6c),	 we	 found	 those	 containing	
protected	and	unprotected	heteroaromatic	residues	could	also	
be	coupled	in	high	yields	(e.g.	6e	and	6i).	However,	with	some	
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examples	 (6b,	6d,	 and	6h)	we	 found	 it	 necessary	 to	 increase	
the	equivalents	of	HATU	to	improve	the	yield.		
These	 conditions	 could	 also	 be	 applied	 to	 the	 gram-scale	
synthesis	 of	 6c.	 Following	 a	 series	 of	 aqueous	 washes	 and	
trituration	with	cold	diethyl	ether	to	ensure	complete	removal	
of	 Cyrene	 (See	 ESI	 for	 full	 work-up	 procedure),	 analytically	
pure	product	could	be	isolated	in	quantitative	yield.	
Scheme	 2	 HATU	 mediated	 amide	 bond	 formation:	 Scope	 of	 the	 coupling	 of	 amino	
acids.	 	 Isolated	 yields.	 Free	 acid	 (1	 equiv.,	 0.25	mmol),	 free	 amine	 (1.1	 equiv.,	 0.275	
mmol),	HATU	(1.2	equiv.,	0.3	mmol),	DIPEA	(3	equiv.,	0.75	mmol),	Cyrene	(1.25	mL,	0.2	
M),	rt,	1	h.	a2.5	equiv	HATU.	
Conclusions	
In	summary,	we	have	evaluated	the	utility	of	Cyrene	 in	HATU	
mediated	 amide	 bond	 formation	 as	 a	 direct	 alternative	 to	
conventional	 solvents	 (DMF,	NMP).	The	conditions	developed	
demonstrate	broad	generality	 and	 functional	 group	 tolerance	
and	could	be	applied	to	the	synthesis	of	both	small	molecules	
and	peptides.		
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